drugset / Trial / NCT01069653

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

NCT01069653

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A\*2402 restricted epitope peptides CDCA1 and KIF20A emulsified with Montanide ISA 51 for advanced small cell lung cancers.

Timeline

Start
2010-02
Primary completion
2019-03
Completion
2019-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CDCA1 Peptide 1 mg Subcutaneous
Subject CDCA1 Peptide 2 mg Subcutaneous
Subject CDCA1 Peptide 3 mg Subcutaneous
Subject KIF20A Peptide 1 mg Subcutaneous
Subject KIF20A Peptide 2 mg Subcutaneous
Subject KIF20A Peptide 3 mg Subcutaneous